Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc lessened its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 18.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 594,325 shares of the company’s stock after selling 133,566 shares during the quarter. Ensign Peak Advisors Inc owned approximately 1.56% of Tarsus Pharmaceuticals worth $16,154,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new position in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at about $61,000. Canada Pension Plan Investment Board purchased a new position in Tarsus Pharmaceuticals during the second quarter worth approximately $114,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Tarsus Pharmaceuticals by 33.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock valued at $166,000 after purchasing an additional 1,530 shares during the last quarter. Bleakley Financial Group LLC purchased a new stake in shares of Tarsus Pharmaceuticals during the 1st quarter valued at $223,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Tarsus Pharmaceuticals by 71.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,567 shares of the company’s stock worth $239,000 after buying an additional 2,735 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Trading Down 3.9 %

TARS stock opened at $33.18 on Tuesday. The company has a current ratio of 7.03, a quick ratio of 6.99 and a debt-to-equity ratio of 0.28. The firm has a market cap of $1.25 billion, a P/E ratio of -6.96 and a beta of 1.06. Tarsus Pharmaceuticals, Inc. has a 1-year low of $12.57 and a 1-year high of $42.50. The business’s 50 day moving average is $27.44 and its 200-day moving average is $30.98.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative return on equity of 63.99% and a negative net margin of 180.00%. The firm had revenue of $40.81 million during the quarter, compared to analyst estimates of $31.30 million. During the same period in the prior year, the company posted ($1.17) earnings per share. Equities analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Oppenheimer reissued an “outperform” rating and issued a $63.00 target price (up previously from $61.00) on shares of Tarsus Pharmaceuticals in a research note on Friday, August 9th. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $51.60.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.